Brainstorm Cell Therapeutics (NASDAQ:BCLI) Raised to Hold at StockNews.com

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

Brainstorm Cell Therapeutics Stock Up 21.7 %

BCLI opened at $2.30 on Monday. The firm has a market cap of $13.11 million, a price-to-earnings ratio of -0.48 and a beta of 0.29. Brainstorm Cell Therapeutics has a 52 week low of $1.05 and a 52 week high of $11.89. The business’s 50 day moving average is $1.83 and its two-hundred day moving average is $3.09.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.